|
WO2020208083A1
|
|
Novel psma specific binding proteins for cancer diagnosis and treatment
|
|
WO2020157281A1
|
|
Immunoglobulin binding proteins for affinity purification
|
|
WO2020127224A1
|
|
Novel folr1 specific binding proteins for cancer diagnosis and treatment
|
|
WO2020099442A1
|
|
Novel triple-helical polypeptides lacking binding affinity for the fc domain of immunoglobulin and uses thereof
|
|
EP3650465A1
|
|
Novel populations of polypeptides having a triple-helical structure
|
|
EP3706804A1
|
|
Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
|
|
EP3452097A1
|
|
Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
|
|
WO2017149002A1
|
|
Novel fusion proteins for capturing of cells
|
|
EP3325514A1
|
|
Her2 binding proteins based on di-ubiquitin muteins
|
|
AU2016295024A1
|
|
Her2 binding proteins based on di-ubiquitin muteins
|
|
EP3325515A1
|
|
Novel binding proteins based on di-ubiquitin muteins and methods for generation
|
|
CA2991815A1
|
|
Novel binding proteins based on di-ubiquitin muteins and methods for generation
|
|
CA2991812A1
|
|
Novel immunoglobulin-binding proteins and their use in affinity purification
|
|
US2018030140A1
|
|
Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
|
|
CA2975362A1
|
|
Novel egfr binding proteins
|
|
EP2721152A1
|
|
Dimeric binding proteins based on modified ubiquitins
|
